SCHEMBL2905657

SCHEMBL2905657

C=C(F)c1ccc(N(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
ALDH1A1 P00352 8/20 0.54
HPGD P15428 3/20 0.54
MAPT P10636 3/20 0.54
TSHR P16473 5/20 0.52
ALOX15 P16050 4/20 0.52
HSD17B10 Q99714 2/20 0.52
MAPK1 P28482 5/20 0.52
CYP3A4 P08684 4/20 0.52
HBB P68871 1/20 0.52
GAA P10253 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 3/20 0.47
GFER P55789 1/20 0.44
SLC2A1 P11166 1/20 0.43
POLB P06746 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905652 1.00 MEN1 (0.57) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL12679042 0.80 MEN1 (0.83) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL441802 0.80 MEN1 (0.83) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL2906433 0.78 MEN1 (0.59) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL608828 0.78 MEN1 (0.59) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL7723077 0.78 KMT2A (0.65) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL14321479 0.76 ALDH1A1 (0.54) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL17122867 0.76 MEN1 (0.57) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL13550714 0.76 ALDH1A1 (0.67) MEN1KMT2AALDH1A1HPGDMAPT
SCHEMBL19675411 0.74 MEN1 (0.55) MEN1KMT2AALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2759543-B1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORP (JP) 2017-07-19 EP disclosed
US-9487693-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2016-11-08 US disclosed
EP-2725017-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2016-06-29 EP disclosed
EP-2669277-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-07-01 EP disclosed
EP-2684886-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-06-03 EP disclosed
EP-2669278-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2015-05-27 EP disclosed
US-8916071-B2 Chromene compound and curable composition TOKUYAMA CORPORATION (JP) 2014-12-23 US disclosed
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-08-14 US disclosed
EP-2759543-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION Tokuyama Corporation (JP) 2014-07-30 EP disclosed
US-8778236-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-07-15 US disclosed
EP-1655293-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 MEN1 2481/4885KMT2A 1153/4885ALDH1A1 2905/4885
US-20140225050-A1 CHROMENE COMPOUND AND CURABLE COMPOSITION CRY2, CRY1, CDYL MEN1 3158/4885KMT2A 997/4885ALDH1A1 2550/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 MEN1 2413/4885KMT2A 1159/4885ALDH1A1 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.